Cardiovascular Clinical Trials

Statistical methods in cardiovascular trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All cardiovascular trials

672 results

• AEGEANIndependent statistical analysis of Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 4Results postedn = 1,217NCT01884350
• AFCAREIndependent statistical analysis of Feasibility Study to Improve AF Outcomes Using a Digital Application for CV Risk Reduction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 11NCT04050982
• AFFILIATEIndependent statistical analysis of Effects of Oral Sildenafil on Mortality in Adults With PAH: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02060487).Phase 4Results postedn = 385NCT02060487
• AFFIRMAn independent statistical analysis of the AFFIRM phase 3 trial of rhythm-management and rate-control strategies in patients with atrial fibrillation. Includes trial design, endpoints, planned statistical analysis, interpretation, and limitations based on…Phase 3NCT00000556
• Aflibercept for Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Aflibercept for Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00437034).Phase 2Results postedn = 6NCT00437034
• AHEADIndependent statistical analysis of Cardiovalve Transfemoral Mitral Valve System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03813524).Phase NAResults postedn = 1NCT03813524
• ALIASIndependent statistical analysis of ALIAS, a randomized phase 3 trial of albumin versus saline in acute ischemic stroke, including trial design, endpoints, logistic regression, risk ratios, nonparametric analysis, safety, and interpretation.Phase 3Results postedn = 841NCT00235495
• ALLIndependent statistical analysis of Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 4,856NCT02299791
• ALLAYIndependent statistical analysis of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension: primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 460NCT00219141
• ALLHATA detailed statistical analysis of ALLHAT, the randomized phase 3 Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, including trial design, endpoints, planned statistical analysis, interpretation, and limitations.Phase 3NCT00000542
• ALPACSIndependent statistical analysis of Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00728988).Phase 4Results postedn = 499NCT00728988
• Altering Activation Patterns Post-stroke: Complete Statistical AnalysisIndependent statistical analysis of Altering Activation Patterns Post-stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02418949).Phase NAResults postedn = 96NCT02418949
• AMBER IIIndependent statistical analysis of A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH): primary endpoint results, effect estimate…Phase 3Results postedn = 19NCT01894022
• ambrisentanIndependent statistical analysis of Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 20NCT01072669
• AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate…Phase 1Results postedn = 141NCT02675452
• Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04790279).Phase 4Results postedn = 175NCT04790279
• Amplatzer Amulet China Post Market Study (PMS): Complete Statistical AnalysisIndependent statistical analysis of Amplatzer Amulet China Post Market Study (PMS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06189365).Phase NAResults postedn = 50NCT06189365
• AMPLITUDE-OIndependent statistical analysis of the phase 3 AMPLITUDE-O trial of efpeglenatide in people with type 2 diabetes, including randomized design, time-to-event endpoints, non-inferiority and superiority analyses, hazard ratios, confidence intervals, and statistical…Phase 3Results postedn = 4,076NCT03496298
• An Evaluation of the Safety and Performance of the CathVision ECGenius® System.: Complete Statistical AnalysisIndependent statistical analysis of An Evaluation of the Safety and Performance of the CathVision ECGenius® System.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 27NCT05301803
• An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension: Complete Statistical AnalysisIndependent statistical analysis of An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 4Results postedn = 178NCT00412932
• An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041): Complete Statistical AnalysisIndependent statistical analysis of An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041):…Phase 4Results postedn = 172NCT00644332
• ANGEL-ASPECTIndependent statistical analysis of ANGEL-ASPECT, a randomized trial of endovascular therapy versus best medical management in acute ischemic stroke patients with large infarct core.Phase NAn = 456NCT04551664
• ANSWERIndependent statistical analysis of Adjunctive Neurovascular Support for Wide-neck Aneurysm Embolization and Reconstruction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02312856).Phase NAResults postedn = 34NCT02312856
• APACAR2Independent statistical analysis of A Comparative Study Between a Pre-hospital and an In-hospital Circulatory Support Strategy (ECMO) in Refractory Cardiac Arrest (APACAR2): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 65NCT02527031
• Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02889562).Phase 2/3Results postedn = 56NCT02889562
• APOLLOIndependent statistical analysis of the APOLLO trial evaluating the Medtronic Intrepid Transcatheter Mitral Valve Replacement System in patients with severe symptomatic mitral regurgitation, including trial design, endpoints, methodology, and statistical interpretation.Phase NAn = 1,056NCT03242642
• APOLLOIndependent statistical analysis of Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 366NCT03469349
• Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias: Complete Statistical AnalysisIndependent statistical analysis of Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 419,927NCT03335800
• AQUACEL® Ag+ Extra™ and Cutimed™ Sorbact® Dressing in the Management of Venous Leg Ulcers Over a 12-week Period: Complete Statistical AnalysisIndependent statistical analysis of AQUACEL® Ag+ Extra™ and Cutimed™ Sorbact® Dressing in the Management of Venous Leg Ulcers Over a 12-week Period: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 203NCT05892341
• ARBIndependent statistical analysis of Angiotensin II Blockade and Inflammation in Obesity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01684748).Phase 4Results postedn = 20NCT01684748
• ARESTIndependent statistical analysis of Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 91NCT02283294
• ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection: Complete Statistical AnalysisIndependent statistical analysis of ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 21NCT02380716
• ARISTOTLEIndependent statistical analysis of ARISTOTLE (NCT00412984), including trial design, time-to-event endpoints, Cox proportional-hazards methodology, hazard ratios, confidence intervals, safety results, and statistical interpretation.Phase 3Results postedn = 20,976NCT00412984
• ARRIVEIndependent statistical analysis of A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 12,546NCT00501059
• ARTS-HFIndependent statistical analysis of the ARTS-HF phase 2 trial of finerenone in worsening chronic heart failure with left ventricular systolic dysfunction and selected diabetes or chronic kidney disease populations.Phase 2Results postedn = 1,066NCT01807221
• ASCENTIndependent statistical analysis of Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 412NCT00942994
• ASIA MRI ICDIndependent statistical analysis of A Post-market Clinical Evaluation of St. Jude Medical™ MR Conditional ICD System on Patients Undergoing Magnetic Resonance Imaging: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 205NCT02877693
• Aspirin and Enoxaparin for VTE in Trauma: Complete Statistical AnalysisIndependent statistical analysis of Aspirin and Enoxaparin for VTE in Trauma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02396732).Phase 4Results postedn = 31NCT02396732
• Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI: Complete Statistical AnalysisIndependent statistical analysis of Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03367312).Phase 2Results postedn = 11NCT03367312
• Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics: Complete Statistical AnalysisIndependent statistical analysis of Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 4NCT01457053
• Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE): Complete Statistical AnalysisIndependent statistical analysis of Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 1,462NCT03067441
• ATHENAComplete statistical analysis of the ATHENA phase 3 trial of dronedarone versus placebo in patients with atrial fibrillation or atrial flutter, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, and statistical…Phase 3Results postedn = 4,628NCT00174785
• ATLANTICIndependent statistical analysis of ATLANTIC (NCT01347580), a randomized phase 4 trial comparing pre-hospital versus in-hospital initiation of ticagrelor in STEMI patients planned for PCI.Phase 4Results postedn = 1,875NCT01347580
• ATLANTISIndependent statistical analysis of the randomized phase 3 ATLANTIS trial evaluating apixaban versus standard of care after trans-aortic valve implantation for aortic stenosis, including trial design, the composite primary endpoint, planned statistical…Phase 3n = 1,510NCT02664649
• ATLASIndependent statistical analysis of Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 35NCT03109795
• Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF): Complete Statistical AnalysisIndependent statistical analysis of Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00252967).Phase 3Results postedn = 64NCT00252967
• Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A): Complete Statistical AnalysisIndependent statistical analysis of Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 7,554NCT00249873
• ATTIndependent statistical analysis of Aquatic Treadmill Therapy for Improving Gait, Balance, Fitness and Quality of Life in Stroke Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 9NCT00983827
• Attain Performa(TM) Quadripolar Lead Study: Complete Statistical AnalysisIndependent statistical analysis of Attain Performa(TM) Quadripolar Lead Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01751022).Phase NAResults postedn = 1,202NCT01751022
• Attain Success Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Attain Success Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00990964).Phase NAResults postedn = 2,014NCT00990964

← All therapeutic areas